NASDAQ:ACHV - Achieve Life Sciences Stock Price, Forecast & News

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Shares of Achieve Life Sciences reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.

Achieve Life Sciences Inc (NASDAQ:ACHV) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.23. View Achieve Life Sciences' Earnings History.

Achieve Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Achieve Life Sciences.

2 brokerages have issued 12 month target prices for Achieve Life Sciences' stock. Their forecasts range from $6.00 to $20.00. On average, they anticipate Achieve Life Sciences' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 2,392.8% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.

Media headlines about ACHV stock have trended very negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achieve Life Sciences earned a daily sentiment score of -3.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Achieve Life Sciences.

Some companies that are related to Achieve Life Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX), Novavax (NVAX), Onconova Therapeutics (ONTX), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Protalix Biotherapeutics (PLX) and Acasti Pharma (ACST).

Achieve Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.10%) and Searle & CO. (1.35%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart. View Institutional Ownership Trends for Achieve Life Sciences.

ACHV stock was sold by a variety of institutional investors in the last quarter, including Searle & CO.. View Insider Buying and Selling for Achieve Life Sciences.

ACHV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund and Richard Alistair Stewart. View Insider Buying and Selling for Achieve Life Sciences.

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHV stock can currently be purchased for approximately $0.52.

Achieve Life Sciences has a market capitalization of $4.35 million. The biopharmaceutical company earns $-12,690,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.View Additional Information About Achieve Life Sciences.

The official website for Achieve Life Sciences is http://www.achievelifesciences.com/.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]